BridgeBio Pharma Inc. (BBIO)
BridgeBio Pharma Statistics
Share Statistics
BridgeBio Pharma has 189.86M shares outstanding. The number of shares has increased by 1.64% in one year.
| Shares Outstanding | 189.86M |
| Shares Change (YoY) | 1.64% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 93.73% |
| Shares Floating | 155.23M |
| Failed to Deliver (FTD) Shares | 40 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 22.31M, so 11.73% of the outstanding shares have been sold short.
| Short Interest | 22.31M |
| Short % of Shares Out | 11.73% |
| Short % of Float | 17.95% |
| Short Ratio (days to cover) | 7.35 |
Valuation Ratios
The PE ratio is -9.53 and the forward PE ratio is -14.26. BridgeBio Pharma's PEG ratio is 0.35.
| PE Ratio | -9.53 |
| Forward PE | -14.26 |
| PS Ratio | 23.01 |
| Forward PS | 3.1 |
| PB Ratio | -3.5 |
| P/FCF Ratio | -9.79 |
| PEG Ratio | 0.35 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BridgeBio Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of -1.19.
| Current Ratio | 4.67 |
| Quick Ratio | 4.67 |
| Debt / Equity | -1.19 |
| Debt / EBITDA | -3.96 |
| Debt / FCF | -3.32 |
| Interest Coverage | -5.97 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $306.07K |
| Profits Per Employee | $-738.98K |
| Employee Count | 725 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.15M |
| Effective Tax Rate | -0.21% |
Stock Price Statistics
The stock price has increased by 41.88% in the last 52 weeks. The beta is 1.08, so BridgeBio Pharma's price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | 41.88% |
| 50-Day Moving Average | 34.19 |
| 200-Day Moving Average | 29.2 |
| Relative Strength Index (RSI) | 66.17 |
| Average Volume (20 Days) | 2.99M |
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 221.9M and earned -535.76M in profits. Earnings per share was -2.88.
| Revenue | 221.9M |
| Gross Profit | 218.02M |
| Operating Income | -592.97M |
| Net Income | -535.76M |
| EBITDA | -436.83M |
| EBIT | -442.9M |
| Earnings Per Share (EPS) | -2.88 |
Balance Sheet
The company has 681.1M in cash and 1.73B in debt, giving a net cash position of -1.05B.
| Cash & Cash Equivalents | 681.1M |
| Total Debt | 1.73B |
| Net Cash | -1.05B |
| Retained Earnings | -3.1B |
| Total Assets | 919.34M |
| Working Capital | 679.38M |
Cash Flow
In the last 12 months, operating cash flow was -520.73M and capital expenditures -933K, giving a free cash flow of -521.66M.
| Operating Cash Flow | -520.73M |
| Capital Expenditures | -933K |
| Free Cash Flow | -521.66M |
| FCF Per Share | -2.8 |
Margins
Gross margin is 98.25%, with operating and profit margins of -267.22% and -241.44%.
| Gross Margin | 98.25% |
| Operating Margin | -267.22% |
| Pretax Margin | -244.34% |
| Profit Margin | -241.44% |
| EBITDA Margin | -196.86% |
| EBIT Margin | -267.22% |
| FCF Margin | -235.09% |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BBIO is $50, which is 30.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $50 |
| Price Target Difference | 30.4% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | -3.46 |
| Piotroski F-Score | 4 |